Carisma Therapeutics Inc (NASDAQ: CARM) on Tuesday, plunged -14.70% from the previous trading day, before settling in for the closing price of $0.28. Within the past 52 weeks, CARM’s price has moved between $0.14 and $1.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 42.71% over the last five years. The company achieved an average annual earnings per share of 52.74%. With a float of $21.12 million, this company’s outstanding shares have now reached $41.79 million.
The firm has a total of 46 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.37%, operating margin of -260.48%, and the pretax margin is -254.28%.
Carisma Therapeutics Inc (CARM) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Carisma Therapeutics Inc is 49.46%, while institutional ownership is 4.29%.
Carisma Therapeutics Inc (CARM) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.31 earnings per share (EPS) for the period topping the consensus outlook (set at -0.36) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.95% during the next five years compared to 42.71% growth over the previous five years of trading.
Carisma Therapeutics Inc (NASDAQ: CARM) Trading Performance Indicators
Carisma Therapeutics Inc (CARM) is currently performing well based on its current performance indicators. A quick ratio of 0.48 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Carisma Therapeutics Inc (CARM)
Analysing the last 5-days average volume posted by the [Carisma Therapeutics Inc, CARM], we can find that recorded value of 0.48 million was lower than the volume posted last year of 5.86 million. As of the previous 9 days, the stock’s Stochastic %D was 31.21%.
During the past 100 days, Carisma Therapeutics Inc’s (CARM) raw stochastic average was set at 8.53%, which indicates a significant increase from 7.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0267 in the past 14 days, which was lower than the 0.0441 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3912, while its 200-day Moving Average is $0.4400. Now, the first resistance to watch is $0.2739. This is followed by the second major resistance level at $0.3097. The third major resistance level sits at $0.3317. If the price goes on to break the first support level at $0.2161, it is likely to go to the next support level at $0.1941. Should the price break the second support level, the third support level stands at $0.1583.
Carisma Therapeutics Inc (NASDAQ: CARM) Key Stats
Market capitalization of the company is 9.95 million based on 41,788K outstanding shares. Right now, sales total 19,630 K and income totals -60,480 K. The company made 3,730 K in profit during its latest quarter, and -9,270 K in sales during its previous quarter.
